Loading clinical trials...
Loading clinical trials...
A Phase III Randomized Controlled Clinical Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Urothelial Carcinoma After Failure of PD-1/PD-L1 Monoclonal Antibody and Platinum-based Chemotherapy
Conditions
Interventions
BL-B01D1
Docetaxel or Paclitaxel
Locations
1
China
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China
Start Date
March 25, 2025
Primary Completion Date
June 1, 2027
Completion Date
December 1, 2027
Last Updated
April 20, 2026
NCT04693377
NCT04895709
NCT06948552
NCT05987241
NCT07061964
NCT04977453
Lead Sponsor
Sichuan Baili Pharmaceutical Co., Ltd.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions